Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury (NEUROGAIT)

Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Study Overview

• Status: Not yet recruiting
• Conditions: Stroke; Walking, Difficulty; Spasticity/Paresis
• Intervention / Treatment: Diagnostic test: Gait analysis

Detailed Description

After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Emilie Hutin, Ph.D.; Phone Number: 0149812549; Email: emilie.hutin@aphp.fr
• Study Contact Backup: Name: Emilie Hutin; Phone Number: 0149812549; Email: emilie.hutin@aphp.fr

Study Locations

• France
  • Créteil, France
    • Laboratoire Analyse et Restauration du Mouvement

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Person with a history of stroke

Description

Inclusion Criteria:

• Adult
• Person who performed tridimensional gait analysis in laboratory
• Person who had a stroke at least 6 months before the gait analysis

Exclusion Criteria:

• Any other neurological pathology or gait disorders
• Botulinum toxin injection in the last 3 months before the gait analysis

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Coefficient of antagonist activation	The coefficient of antagonist activation of gastrocnemius medialis and soleus was calculated from EMG data by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.	1 year

Collaborators and Investigators

• Sponsor: Henri Mondor University Hospital
• Investigators: Principal Investigator: Emilie Hutin, Hôpitaux Universitaires Henri Mondor

Study record dates

Study Major Dates

• Study Start (Estimated): October 19, 2023
• Primary Completion (Estimated): October 19, 2023
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: October 19, 2023
• First Submitted That Met QC Criteria: October 24, 2023
• First Posted (Actual): October 30, 2023

Study Record Updates

• Last Update Posted (Actual): October 30, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Wounds and Injuries; Paresis; Trauma, Nervous System; Mobility Limitation
• Other Study ID Numbers: 2023-A02258-37

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No